Guidelines

Evidence-based recommendations on use of MOVENTIG in treating opioid-induced constipation (OIC) have been produced by NICE (National Institute for Health and Care Excellence) and the SMC (Scottish Medicines Consortium).

NICE guidance

MOVENTIG is recommended as an option for treating OIC.

Naloxegol is recommended, within its marketing authorisation, as an option for treating opioid-induced constipation in adults whose constipation has not adequately responded to laxatives.

An inadequate response is defined as opioid‑induced constipation symptoms of at least moderate severity in at least 1 of the 4 stool symptom domains (that is, incomplete bowel movement, hard stools, straining or false alarms) while taking at least 1 laxative class for at least 4 days during the prior 2 weeks.

Further information can be accessed on the NICE website here:

www.nice.org.uk/guidance/ta345/chapter/1-Guidance

SMC advice

Following a full submission, naloxegol (MOVENTIG) is accepted for use within NHS Scotland.

Indication under review: The treatment of opioid-induced constipation in adult patients who have had an inadequate response to laxative(s). Naloxegol compared to placebo significantly improved the response rate in patients with opioid-induced constipation, including patients who had previously had an inadequate response to at least four days of treatment with at least one class of laxative.

Further information can be accessed on the SMC website here:

https://www.scottishmedicines.org.uk/medicines-advice/naloxegol-moventig-fullsubmission-110615/